Clinical Trial Update: T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a combination of T-cell infusion, Aldesleukin (IL-2), and Utomilumab in recurrent ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Aldesleukin (interleukin-2)
• T-cell infusion
• Utomilumab (utomilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: COL6A3 Positive, HLA-A*0201 Positive Cells Present | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-11-07